Physician profile
Jonathan Chang
NPI 1114968385
$65,875.23
in general payments reported to CMS, 2019-2025
51 companies · $7,830 in 2025
The $7,830 reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17K · 2020: $5,913 · 2021: $9,062 · 2022: $8,790 · 2023: $6,766 · 2024: $10K · 2025: $7,830.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $16K · Food and Beverage: $7,756 · Travel and Lodging: $876 · Education: $41.52.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $15,980.00 |
| Food and Beverage | $7,756.34 |
| Travel and Lodging | $875.56 |
| Education | $41.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $43,907.18 | 2019-2025 | Vemlidy, Livdelzi |
| Amgen INC. | $5,107.20 | 2019-2025 | Evenity, Prolia, Krystexxa |
| Astrazeneca Pharmaceuticals Lp | $2,213.72 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Esperion Therapeutics, INC. | $1,753.07 | 2020-2025 | Nexletol |
| Glaxosmithkline, LLC. | $1,610.25 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $1,514.86 | 2019-2025 | Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $987.78 | 2019-2025 | Jardiance, Synjardy |
| Amarin Pharma, INC. | $973.36 | 2019-2023 | |
| Abbvie INC. | $904.30 | 2021-2025 | Ubrelvy, Linzess |
| Lilly USA, LLC | $728.53 | 2019-2024 | Mounjaro, Jardiance, Emgality |
| Pfizer INC. | $565.06 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $469.92 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $466.81 | 2019-2023 | Dificid |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $415.44 | 2019-2024 | Xifaxan, Trulance |
| Astellas Pharma US INC | $409.63 | 2019-2024 | Veozah, Myrbetriq |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Chang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.